XOMA XOMA Corporation

21.8
+0.29  (+1%)
Previous Close 21.51
Open 21.64
Price To Book
Market Cap 190,269,033
Shares 8,727,617
Volume 6,467
Short Ratio
Av. Daily Volume 56,430

NewsSee all news

  1. XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company's business at the H.C. Wainwright

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
BLA filing due 4Q 2019.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 2 proof-of-concept results released April 24, 2017.
XOMA 213
Hyperprolactinemia
Phase 1 initiation of patient dosing announced June 13, 2019.
Gevokizumab
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma

Latest News

  1. XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company's business at the H.C. Wainwright